-
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)
What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
Melanoma: Understanding, Diagnosing, and Treating Skin Cancer(Post)Melanoma is an aggressive type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives skin its color. Although it is less common than othe
Osteoimmunology: The RANKL-OPG Axis & Bone Erosion(Page) Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
The Rise of Cancer Neuroscience: How Neural Circuits Drive Tumor Progression(Post)For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
How do different types of vaccines work? (Post)What is a vaccine? A vaccine is a pharmacological product that gives the recieving patient's immune system a chance to learn how to fight infection with decreased risk of illness. Vacci
Immunoglobulin vs Antibody: Unveiling the Intricacies(Post)In the realm of immunology, the terms "immunoglobulin" and "antibody" often find themselves used interchangeably, sparking confusion among those keen on understanding the immune system's fine deta
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease(Post)The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease In the intricate landscape of the human brain, a silent, ever-watchful guardian stands ready to defend against injury and invas
Co-Immunoprecipitation (co-IP) Protocol(Page) Cytokine Release Syndrome and the IL-6 Axis(Page) Trained Immunity: Reprogramming Innate Immune Memory for Future Health(Post)What if our first line of immune defense, the innate immune system, could learn from past encounters to fight future battles more effectively? For decades, we believed this was the exclusive domain of
Antibody Structure: Overview & Insights(Post)Antibody Structure Antibody S
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Narnatumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.
ELISA Troubleshooting: Total Protein Normalization in Lysates(Post)QUICK ANSWER A researcher ran a panel of EMT-marker ELISA kits (E-cadherin, claudin-1, N-cadherin, vimentin, ZEB1, TWIST1) on breast cell-line lysates and found E-cadherin reading "pos
A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve